Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share. This compares to a loss of $3.17 per share a year ago.
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
3 Top Earnings Acceleration Stocks to Buy for 2H25
Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to extend the runway and avoid near-term dilution, but financial risks and execution remain key concerns.
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago.
